Charles M Conway Selected Research

rimegepant sulfate

1/2021	Oral rimegepant for preventive treatment of migraine: a phase 2/3, randomised, double-blind, placebo-controlled trial.
9/2020	Safety of Rimegepant, an Oral CGRP Receptor Antagonist, Plus CGRP Monoclonal Antibodies for Migraine.
1/2020	Potential for treatment benefit of small molecule CGRP receptor antagonist plus monoclonal antibody in migraine therapy.
11/2019	Rimegepant, an Oral Calcitonin Gene-Related Peptide Receptor Antagonist, for Migraine.
1/2019	Efficacy, safety, and tolerability of rimegepant orally disintegrating tablet for the acute treatment of migraine: a randomised, phase 3, double-blind, placebo-controlled trial.

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.

Realize the full power of the drug-disease research graph!

Charles M Conway Research Topics

Disease

14	Migraine Disorders (Migraine) 01/2021 - 08/2008
4	Neuralgia (Stump Neuralgia) 01/2022 - 11/2013
4	Pain (Aches) 11/2019 - 01/2016
2	Hyperalgesia 01/2017 - 01/2016
1	Nausea 01/2019
1	Urinary Tract Infections (Urinary Tract Infection) 01/2019
1	Inflammation (Inflammations) 01/2017
1	Peripheral Nervous System Diseases (PNS Diseases) 01/2016
1	Acute Pain 01/2016
1	Diabetic Neuropathies (Diabetic Neuropathy) 11/2013

Drug/Important Bio-Agent (IBA)

11	Calcitonin Gene-Related Peptide Receptor AntagonistsIBA 01/2021 - 04/2012
9	Calcitonin Gene-Related PeptideIBA 01/2021 - 08/2008
5	rimegepant sulfateIBA 01/2021 - 01/2019
5	Calcitonin Gene-Related Peptide Receptors (Calcitonin-Gene Related Peptide Receptor)IBA 01/2021 - 08/2008
3	Phosphotransferases (Kinase)IBA 01/2022 - 01/2016
2	erenumabIBA 09/2020 - 01/2020
2	Monoclonal AntibodiesIBA 09/2020 - 01/2020
2	Formaldehyde (Formol)FDA Link 01/2016 - 11/2013
2	4- (8- fluoro- 2- oxo- 1,2- dihydroquinazolin- 3(4H)- yl)- N- (3- (7- methyl- 1H- indazol- 5- yl)- 1- oxo- 1- (4- (piperidin- 1- yl)piperidin- 1- yl)propan- 2- yl)piperidine- 1- carboxamideIBA 04/2012 - 08/2008
1	EthersIBA 01/2022
1	AminesIBA 01/2022
1	LigandsIBA 09/2020
1	galcanezumabIBA 09/2020
1	fremanezumabIBA 09/2020
1	TabletsIBA 01/2019
1	Amino Acids FDA Link 01/2017
1	gamma-Aminobutyric Acid (GABA)IBA 01/2017
1	Glycine (Aminoacetic Acid)FDA LinkGeneric 01/2017
1	Glycine Receptors (Glycine Receptor)IBA 01/2017
1	NeuropeptidesIBA 02/2016
1	Streptozocin (Streptozotocin)FDA Link 01/2016
1	Adrenergic Agents (Adrenergic Drugs)IBA 01/2016
1	piperidineIBA 12/2012
1	pyridineIBA 04/2012
1	AmidesIBA 04/2012
1	BMS-846372IBA 04/2012

Therapy/Procedure

2	Therapeutics 01/2020 - 01/2020
1	Ligation 01/2016